FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma
Season 7, Episode 44, Nov 03, 2022, 06:00 PM
Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importance of biomarker testing in the cholangiocarcinoma population.